Brenda Medina is an investigative reporter for ICIJ.
Prior to joining ICIJ in 2021, she was a senior reporting fellow at ProPublica, in New York. Before that, Brenda worked for the Miami Herald/el Nuevo Herald, where she reported in English and Spanish. At the Herald, she covered local government and immigration and worked on investigations about public corruption, housing and labor issues.
Brenda is from the Dominican Republic. She studied journalism and international studies at the University of South Florida and Hillsborough Community College, in Tampa, Florida.
- Investigations
- Stories by Brenda Medina
The case stems from ICIJ’s Cancer Calculus investigation into the world's best-selling drug’s sky-high price and its global consequences.
Jul 10, 2026
In a letter, Sen. Maggie Hassan cited ICIJ's Cancer Calculus investigation and expressed concerns that the pharma giant is boosting profits at the expense of patients.
Jul 02, 2026
The crypto industry and law enforcement groups are in the midst of a lobbying showdown over the proposed Clarity Act.
Jun 24, 2026
Researchers found that Keytruda — the focus of ICIJ's recent Cancer Calculus investigation — accounted for nearly half of the potential annual savings.
Jun 11, 2026
Following the paper trail to Guatemala to uncover what records can’t reveal about access to Keytruda
I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how scarcity shapes life and death decisions.
May 11, 2026
The pharmaceutical giant has built a fortress of patents, traded in secrecy and relentlessly lobbied to guard its revenue kingpin Keytruda.
Apr 13, 2026
As bureaucratic fights to access Keytruda drag on for years, some patients die waiting.
Apr 13, 2026
Across jurisdictions, governments are struggling to rein in a volatile industry worth more than $3 trillion, leading to patchy oversight.
Nov 17, 2025






